Evidence map›Paper›PMID 35487424›Full record

ArticleActa biomaterialia2022

Injectable three-dimensional tumor microenvironments to study mechanobiology in ovarian cancer.

Eric N Horst, Caymen M Novak, Kathleen Burkhard, Catherine S Snyder, Rhea Verma, Darel E Crochran, Izabella A Geza, Wesley Fermanich, Pooja Mehta, Denise C Schlautman and 3 more

Open access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Eric N HorstDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Caymen M NovakDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, The Ohio State University Wexner College of Medicine, Columbus, OH 43210, United States.
Kathleen BurkhardDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Catherine S SnyderDepartment of Materials Science and Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Rhea VermaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Darel E CrochranDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Izabella A GezaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Wesley FermanichDepartment of Materials Science and Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Pooja MehtaDepartment of Materials Science and Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Denise C SchlautmanDepartment of Materials Science and Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Linh A TranDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Michael E BrezengerDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, United States.
Geeta MehtaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, United States; Department of Materials Science and Engineering, University of Michigan, Ann Arbor, MI 48109, United States; Macromolecular Science and Engineering, University of Michigan, Ann Arbor, MI 48109, United States; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, United States; Precision Health, University of Michigan, Ann Arbor, MI 48109, United States. Electronic address: mehtagee@umich.edu.
University of Michigan · USThe Ohio State University Wexner Medical Center · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
Tissue Engineering and RegenerationT32DE007057 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID H. KOHN · 1985 to 2026
$17.3M
NCATS NIH HHS UL1 TR002240NCI NIH HHS P30 CA046592NIDCR NIH HHS T32 DE007057
6 · The paper itself

Abstract

Epithelial ovarian cancers are among the most aggressive forms of gynecological malignancies. Despite the advent of poly adenosine diphosphate-ribose polymerase (PARP) and checkpoint inhibitors, improvement to patient survival has been modest. Limited in part by clinical translation, beneficial therapeutic strategies remain elusive in ovarian cancers. Although elevated levels of extracellular proteins, including collagens, proteoglycans, and glycoproteins, have been linked to chemoresistance, they are often missing from the processes of drug- development and screening. Biophysical and biochemical signaling from the extracellular matrix (ECM) determine cellular phenotype and affect both tumor progression and therapeutic response. However, many state-of-the-art tumor models fail to mimic the complexities of the tumor microenvironment (TME) and omit key signaling components. In this article, two interpenetrating network (IPN) hydrogel scaffold platforms, comprising of alginate-collagen or agarose-collagen, have been characterized for use as 3D in vitro models of epithelial ovarian cancer ECM. These highly tunable, injection mold compatible, and inexpensive IPNs replicate the critical governing physical and chemical signaling present within the ovarian TME. Additionally, an effective and cell-friendly live-cell retrieval method has been established to recover cells post-encapsulation. Lastly, functional mechanotransduction in ovarian cancers was demonstrated by increasing scaffold stiffness within the 3D in vitro ECM models. With these features, the agarose-collagen and alginate-collagen hydrogels provide a robust TME for the study of mechanobiology in epithelial cancers. STATEMENT OF SIGNIFICANCE: Ovarian cancer is the most lethal gynecologic cancer afflicting women today. Here we present the development, characterization, and validation of 3D interpenetrating platforms to shift the paradigm in standard in vitro modeling. These models help elucidate the roles of biophysical and biochemical cues in ovarian cancer progression. The agarose-collagen and alginate-collagen interpenetrating network (IPN) hydrogels are simple to fabricate, inexpensive, and can be modified to create custom mechanical stiffnesses and concentrations of bio-adhesive motifs. Given that investigations into the roles of biophysical characteristics in ovarian cancers have provided incongruent results, we believe that the IPN platforms will be critically important to uncovering molecular drivers. We also expect these platforms to be broadly applicable to studies involving mechanobiology in solid tumors.

Indexed as

Ovarian NeoplasmsTumor MicroenvironmentAlginatesBiophysicsCarcinoma, Ovarian EpithelialCollagenExtracellular MatrixFemaleHumansHydrogelsMechanotransduction, CellularSepharoseAlginatesCollagenHydrogelsSepharoseAgaroseAlginateCancersCollagenExtracellular matrixHydrogelInjectableInterpenetrating networkMechanobiologyOvarian cancersTumor microenvironment

Identifiers

PMID35487424
PMCPMC10538942
OpenAlexW4224930214

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.